Journal article

IPVS statement moving towards elimination of cervical cancer as a public health problem

SM Garland, A Giuliano, JML Brotherton, AB Moscicki, M Stanley, AM Kaufmann, N Bhatla, R Sankaranarayanan, JM Palefsky, S de Sanjose

Papillomavirus Research | ELSEVIER SCIENCE BV | Published : 2018

Grants

Funding Acknowledgements

Professor Suzanne Garland, has received Grants to her institution from Commonwealth Department of Health for HPV genoprevalance surveillance post vaccination, Merck and GSK (GlaxoSmithKline) to perform phase 3 clinical vaccine trials: Merck for an investigator initiated grant to evaluate HPV in RRP post vaccination programme, Seqirus for HPV in Australian cervical cancer HPV genotyping study, & VCA (Victoria Cancer Agency) for a study on effectiveness of public health HPV vaccine on HPV genoprevalence and CIN3 in vaccine-eligible age women. She has received speaking fees from MSD for work performed in her personal time and Merck paid for travel & accommodation to present at HPV Advisory board meetings.Dr. Giuliano's institution has received investigator initiated research grants from Merck & Co, Inc. on her behalf. She is also a member of the Scientific Advisory Board and Global Advisory Board of Merck & Co, Inc.Joel Palefsky: Merck and Co: scientific advisory board, grant support, travel support. No funds to me or my institution.Antiva Biosciences: Grant support, advisory boardAgenovir: Grant support